| Document Date: 2012-09-26 09:41:36
Open Document File Size: 1,08 MBShare Result on Facebook
City Characterization Cell / / Company Mitsui & Co. Ltd. / Progenitor Cells Promethera Biosciences / Promethera Biosciences / Research Partner Conclusion Successes Hurdles 9 Promethera Biosciences / Boehringer Ingelheim Venture Fund / Shire Strategic Investment Group / / Continent Europe / / Country Belgium / / Currency EUR / / / Event FDA Phase / / Facility Promethera Biosciences’ Pipeline / / IndustryTerm treatment of Crigler-Najjar syndrome / treatment of liver diseases / therapy for liver diseases / manufacturing / chemical / pharmaceutical / / MedicalCondition liver diseases / Crigler-Najjar syndrome / Orphan diseases / disorders / dissociation / / MedicalTreatment cell therapy / / Organization FDA / European Parliament / / Person Etienne Sokal / Sambrinvest / Beatrice De Vos / / / Position leader / actor / Professor / Major / Private / / Product Q1 / / Technology cell therapy / transplantation / drug development / /
SocialTag |
The promise of cell therapy for liver diseases: hurdles and success in drug development Beatrice De Vos, MD, PhD, BCPM (CMO PB) Research Symposium on digestive and liver diseases European Parliament, Brussels September 1